MONDAY, June 8, 2026 (HealthDay News) -- Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with reduced risks for thromboembolic events, emergency department use, and mortality among adults with obesity and autoimmune diseases (AIDs), according to a study published online June 6 in the Journal of the American Heart Association to coincide with the annual meeting of the American Diabetes Association, held from June 5 to 8 in New Orleans.Hao Dai, Ph.D., from the Indiana University School of Medicine in Indianapolis, and colleagues conducted a retrospective cohort study, which emulated a target trial using 2014 to 2024 electronic health record data to examine the association between GLP-1 RA use and major adverse cardiovascular and thromboembolic event risk among adults with obesity and AID
Also, they stimulate the endothelium to produce nitric oxide, reduce oxidative stress, and have antiatherogenic and anti-inflammatory effects
D., & Edden, R
Effects of 12 months of treatment with disease-modifying anti-rheumatic drugs on low and high density lipoprotein subclass distribution in patients with early rheumatoid arthritis: a pilot study
Where is BAC Water 30Ml made
Body Composition Testing Learn About Body Composition Testing Gain deeper insights into your bodys metrics with our advanced testing
